Holen Sie sich die Stockscreener-App
0.357
0.00%
0.00
Handel nachbörslich:
.35
-0.007
-1.96%
Schlusskurs vom Vortag:
$0.357
Offen:
$0.366
24-Stunden-Volumen:
397.88K
Relative Volume:
1.14
Marktkapitalisierung:
$27.65M
Einnahmen:
$1.22M
Nettoeinkommen (Verlust:
$-14.15M
KGV:
-1.3731
EPS:
-0.26
Netto-Cashflow:
$-6.55M
1W Leistung:
-3.51%
1M Leistung:
+0.28%
6M Leistung:
-16.20%
1J Leistung:
+27.05%
1-Tages-Spanne:
$0.345
$0.3663
1-Wochen-Bereich:
$0.33
$0.38
52-Wochen-Spanne:
$0.265
$0.9099
IGC Pharma Inc Stock (IGC) Company Profile
Firmenname
IGC Pharma Inc
Sektor
Branche
Telefon
301-983-0998
Adresse
4336 Montgomery Avenue, Bethesda, MD
Vergleichen Sie IGC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.357 | 27.65M | 1.22M | -14.15M | -6.55M | -0.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.11 | 104.84B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.15 | 78.92B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
621.29 | 37.15B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.28 | 30.22B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
115.79 | 27.76B | 3.30B | -501.07M | 1.03B | -2.1146 |
IGC Pharma Inc Aktie (IGC) Neueste Nachrichten
IGC Pharma to Present at BIO Partnering @ JPM 2025 Healthcare Conference - StockTitan
IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025 - AccessWire
What Makes IGC Pharma, Inc. (IGC) a New Buy Stock - MSN
Ascendiant Capital Markets Forecasts Strong Price Appreciation for IGC Pharma (NYSEMKT:IGC) Stock - Defense World
IGC Pharma expands clinical research program for IGC-AD1 - Nasdaq
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer's Therapy Addressing Cognitive Impairment and Underlying Disease Pathology - AccessWire
IGC Pharma's Alzheimer's Drug Shows 50% Memory Improvement in Early Studies - StockTitan
IGC.WS (India Globalization Capital) EV-to-FCF : 0.00 (As of Nov. 30, 2024) - GuruFocus.com
Otsuka Corp (OSUKF) QuotePress Release - The Globe and Mail
Cannabinoid Drug For Agitation In Alzheimer's Yields Cognitive Improvements In Clinical Trial - Inkl
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer's Treatment - BioSpace
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of He - GuruFocus.com
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasin - GuruFocus.com
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline - WSIL TV
IGC (IGC Pharma) Price-to-Operating-Cash-Flow : (As of Nov. 14, 2024) - GuruFocus.com
IGC Pharma Reports 42% Revenue Growth, Advances Multiple Alzheimer's Drug Candidates | IGC Stock News - StockTitan
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies - AccessWire
IGC Pharma CEO Reveals AI-Driven Strategy in Alzheimer's and Weight Loss Drug Development | IGC Stock News - StockTitan
IGC Pharma (STU:IGS1) Asset Turnover : 0.03 (As of Jun. 2024) - GuruFocus.com
MD’s IGC Pharma enrolls patients in Phase 2 trial for Alzheimer’s dementia drug - Maryland Daily Record
IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1 - AccessWire
Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts - Seeking Alpha
A Guide To The Risks Of Investing In IGC Pharma Inc (IGC) - Knox Daily
Investor’s Delight: IGC Pharma Inc (IGC) Closes Strong at 0.37, Up 0.13 - The Dwinnex
Was IGC Pharma Inc (IGC)’s session last reading good? - US Post News
BioMedNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Announces Stockholders’ Approval of All Disclosed Proposals at 2024 Annual Meeting - MSN
IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge - Markets Insider
Financial Metrics Check: IGC Pharma Inc (IGC)’s Ratios for Trailing Twelve Months - The Dwinnex
A Look at IGC Pharma Inc (IGC) Shares in the Recent Past Indicates Growth - SETE News
IGC Pharma Inc’s latest rating changes from various analysts - Knox Daily
IGC’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
Is IGC Pharma Inc (AMEX:IGC) stock a better investment at this time? - US Post News
AvePoint Inc’s latest rating changes from various analysts - Knox Daily
IGC Pharma Inc (AMEX: IGC) Down -0.99% This Year: What Is Going To Happen Next - Stocks Register
IGC Pharma director James Moran buys $200k in company stock - Investing.com Australia
IGC Pharma director James Moran buys $200k in company stock By Investing.com - Investing.com South Africa
Ipca Labs shares hit lifetime high after Nomura raises target price - Business Standard
IPCA Labs shares hit fresh 52-week high as Nomura upgrades target price on strong growth plans - Moneycontrol
Ipca Labs Shares Hit Life High As Nomura Hikes Target Price - NDTV Profit
Nomura expects IPCA Labs shares to rally over 20% from current price, retains Buy call - Business Upturn
EC approves Iqirvo plus UDCA to treat primary biliary cholangitis - World Pharmaceutical Frontiers
IPCA Laboratories Looking to Consolidate US Generics Business; Shares Gain - EquityPandit
Ipca Laboratories to Consolidate US Generics Business; Shares Up 1% - Indiainfoline
Ipca Laboratories to consider consolidaton of US generics business - CNBCTV18
StockNews.com Upgrades ICL Group (NYSE:ICL) to Strong-Buy - MarketBeat
Ipsen’s Iqirvo approved in Europe - The Pharma Letter
ICL Group (NYSE:ICL) Hits New 12-Month Low at $3.80 - MarketBeat
Ipsen’s Iqirvo® (elafibranor) approved in the European - GlobeNewswire
Ratio Revelations: IGC Pharma Inc (IGC)’s Financial Metrics in the Spotlight - The Dwinnex
Finanzdaten der IGC Pharma Inc-Aktie (IGC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.60%
2.24%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):